Successful Sequential Treatment for Severe Asthma Coexisting COVID-19 via Budesonide/Glycopyrrolate/Formoterol Fumarate

Liang, Yingjian; Chen, Meizhu; Tan, Cuiyan; Tu, Changli; Zheng, Xiaobin; Liu, Jing

doi:10.2147/ijgm.s291695

Cited by 2 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The age of the patients ranged from 15 to 80 years old (median 47.4 years old). Among the 102 patients, 1 patient (male) had a history of asthma, 20 1 had allergic rhinitis, 6 patients had a cured malignancy, 6 had a history of diabetes and 16 had a history of hypertension. The major clinical symptoms were fever, shortness of breath, cough, diarrhoea, loss of appetite, haemoptysis, fatigue, chest tightness and sputum production.…”

Section: Resultsmentioning

confidence: 99%

Hypersensitivity may be involved in severe COVID‐19

Tan

Zheng

Sun

et al. 2021

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

Background Deaths attributed to Coronavirus Disease 2019 (COVID‐19) are mainly due to severe hypoxemic respiratory failure. Although the inflammatory storm has been considered the main pathogenesis of severe COVID‐19, hypersensitivity may be another important mechanism involved in severe cases, which have a perfect response to corticosteroids (CS). Method We detected the serum level of anti‐SARS‐CoV‐2–spike S1 protein‐specific IgE (SP‐IgE) and anti‐SARS‐CoV‐2 nucleocapsid protein‐specific IgE (NP‐IgE) in COVID‐19. Correlation of levels of specific IgE and clinical severity were analysed. Pulmonary function test and bronchial provocation test were conducted in early convalescence of COVID‐19. We also obtained histological samples via endoscopy to detect the evidence of mast cell activation. Result The levels of serum SP‐IgE and NP‐IgE were significantly higher in severe cases, and were correlated with the total lung severity scores (TLSS) and the PaO 2 /FiO 2 ratio. Nucleocapsid protein could be detected in both airway and intestinal tissues, which was stained positive together with activated mast cells, binded with IgE. Airway hyperresponsiveness (AHR) exists in the early convalescence of COVID‐19. After the application of CS in severe COVID‐19, SP‐IgE and NP‐IgE decreased, but maintained at a high level. Conclusion Hypersensitivity may be involved in severe COVID‐19.

show abstract

Section: Resultsmentioning

confidence: 99%

Hypersensitivity may be involved in severe COVID‐19

Tan

Zheng

Sun

et al. 2021

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, this patient had a smoking history and emphysema visible in the computed tomography scan, which supports the diagnosis of COPD and therefore makes it difficult to interpret these results. 65 …”

Section: Resultsmentioning

confidence: 99%

“…The latter is, so far, promising, but it is impossible at this point to take any definite conclusions on this matter. 65 …”

Section: Discussionmentioning

confidence: 99%

Understanding and Managing Severe Asthma in the Context of COVID-19

Cardoso¹,

Ribeiro²,

Aguiar³

et al. 2021

ITT

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) continues to spread across the world. Since the beginning of the pandemic, the question of whether asthma is a risk factor for getting the infection or for poor outcomes motivated a great debate. In the field of severe asthma and its treatment during COVID-19 pandemic, several issues are also pending. A literature review focused on the management of severe asthma patients in the context of COVID-19 is performed. The available evidence suggests that severe asthma patients do not have an increased risk of poor COVID-19 outcomes and that it is safe to treat asthmatic patients with inhaled corticosteroids (ICS) and biologics during the pandemic, even though some studies indicate that high doses of ICS may predispose to COVID-19. The chronic use of oral corticosteroid (OCS) might be associated with poor COVID-19 outcomes, although there is no complete agreement. There is very limited evidence concerning the use of triple therapy for asthma in the context of this pandemic. Ultimately, severe asthma patients should maintain their medication during the COVID-19 pandemic, including biologic agents. More studies are needed to address the role of asthma medications and asthma’s different phenotypes on the incidence and course of COVID-19.

show abstract

Successful Sequential Treatment for Severe Asthma Coexisting COVID-19 via Budesonide/Glycopyrrolate/Formoterol Fumarate

Cited by 2 publications

References 6 publications

Hypersensitivity may be involved in severe COVID‐19

Hypersensitivity may be involved in severe COVID‐19

Understanding and Managing Severe Asthma in the Context of COVID-19

Contact Info

Product

Resources

About